Investments
3Portfolio Exits
1About Kirin Pharma Company
As of April 1, 2008, Kirin Pharma Company, Limited was acquired by Kyowa Hakko Kogyo Co., Ltd. Kirin Pharma Company, Limited manufactures bio-pharmaceutical products. It focuses on renal, cancer, and immune disorder and infectious diseases. It is now headquartered in Japan.
Want to inform investors similar to Kirin Pharma Company about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Kirin Pharma Company Investments
3 Investments
Kirin Pharma Company has made 3 investments. Their latest investment was in CoImmune as part of their Debt - II on September 9, 2010.
Kirin Pharma Company Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
9/13/2010 | Debt - II | CoImmune | $4.85M | No | AAC Capital Partners, Aurora Funds, BD Ventures, CDP Capital, Cordova Ventures, Forbion, GeneChem Therapeutics Venture Fund, Harbinger/Aurora Venture Fund, InterSouth Partners, Japan Asia Investment Group, Kirin Pharma Company, Lumira Ventures, Mizuho Capital, Morningside Ventures, Oakwood Medical Investors, Pacific Horizon Ventures, Sanders Morris Harris Private Equity, Senmed Medical Ventures, Signet Healthcare Partners, Sutter Hill Ventures, TFG Capital Unternehmensbeteiligungsgesellschaft, TVM Capital Life Science, and Vestcorp AG | |
11/21/2008 | Series C - II | |||||
4/14/2008 | Series C |
Date | 9/13/2010 | 11/21/2008 | 4/14/2008 |
|---|---|---|---|
Round | Debt - II | Series C - II | Series C |
Company | CoImmune | ||
Amount | $4.85M | ||
New? | No | ||
Co-Investors | AAC Capital Partners, Aurora Funds, BD Ventures, CDP Capital, Cordova Ventures, Forbion, GeneChem Therapeutics Venture Fund, Harbinger/Aurora Venture Fund, InterSouth Partners, Japan Asia Investment Group, Kirin Pharma Company, Lumira Ventures, Mizuho Capital, Morningside Ventures, Oakwood Medical Investors, Pacific Horizon Ventures, Sanders Morris Harris Private Equity, Senmed Medical Ventures, Signet Healthcare Partners, Sutter Hill Ventures, TFG Capital Unternehmensbeteiligungsgesellschaft, TVM Capital Life Science, and Vestcorp AG | ||
Sources |
Kirin Pharma Company Portfolio Exits
1 Portfolio Exit
Kirin Pharma Company has 1 portfolio exit. Their latest portfolio exit was CoImmune on February 07, 2014.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
